Christopher Liu
Stock Analyst at Lucid Capital
(3.91)
# 1,897
Out of 4,690 analysts
152
Total ratings
44.2%
Success rate
10.1%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Maintained: Buy | $22 → $34 | $23.73 | +43.28% | 3 | Aug 5, 2026 | |
| CRDF Cardiff Oncology | Maintained: Buy | $14 → $4 | $0.94 | +325.53% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Maintained: Buy | $25 | $6.09 | +310.51% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $33.84 | +47.75% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $5 | $1.66 | +202.11% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $4.33 | +223.33% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $1.82 | +229.67% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $11 | $13.82 | -20.41% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $18.28 | +173.58% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $2.22 | +260.36% | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $14.53 | +37.65% | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $3.68 | +144.57% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.66 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.84 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 → $37 | $54.45 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $36 | $26.21 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $3.11 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $40.11 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $34.67 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $18.77 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.85 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $9.18 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $13.38 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $11.57 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $36.44 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $5.29 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.76 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.3266 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $14.48 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.06 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.001 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Aug 5, 2026
Maintained: Buy
Price Target: $22 → $34
Current: $23.73
Upside: +43.28%
Cardiff Oncology
Jun 5, 2026
Maintained: Buy
Price Target: $14 → $4
Current: $0.94
Upside: +325.53%
NextCure
Jun 2, 2026
Maintained: Buy
Price Target: $25
Current: $6.09
Upside: +310.51%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $33.84
Upside: +47.75%
Actuate Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $1.66
Upside: +202.11%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $4.33
Upside: +223.33%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $1.82
Upside: +229.67%
Adlai Nortye Group
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $13.82
Upside: -20.41%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $18.28
Upside: +173.58%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $2.22
Upside: +260.36%
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $14.53
Upside: +37.65%
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $3.68
Upside: +144.57%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.66
Upside: n/a
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.84
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $19 → $37
Current: $54.45
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $26.21
Upside: n/a
Jan 27, 2025
Maintained: Buy
Price Target: $20
Current: $3.11
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $40.11
Upside: n/a
Feb 20, 2024
Maintained: Buy
Price Target: n/a
Current: $34.67
Upside: n/a
Feb 13, 2024
Maintained: Buy
Price Target: $18
Current: $18.77
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $3.85
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $9.18
Upside: n/a
Nov 9, 2023
Maintained: Hold
Price Target: $5
Current: $13.38
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $11.57
Upside: n/a
Aug 2, 2018
Rated: Hold
Price Target: n/a
Current: $36.44
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $5.29
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $25.76
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.3266
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $14.48
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $1.06
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.001
Upside: n/a